 |
|
|
| |
Pharmacokinetic and 4-week safety/efficacy of dolutegravir (S/GSK1349572) dispersible tablets in HIV-infected children aged 4 weeks to <6 years: results from IMPAACT P1093
|
| |
| |
Reported by Jules Levin
22nd International AIDS Conference (AIDS 2018), Amsterdam, Netherlands, 23-27 July 2018
Theodore Ruel1, Edward P. Acosta2, Rajendra Singh3, Carmelita Alvero4, Terry Fenton4, Kathleen George5, Ellen Townley6, Rohan Hazra7, Stephanie Popson8, Ann M. Buchanan9, Cindy Brothers9, Cindy Vavro9, Andrew Wiznia10, and the IMPAACT P1093 Team
Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH), all components ofthe National Institutes of Health (NIH), under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC), and by NICHD contract number HHSN275201800001I.The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
|
| |
|
|
|
|
|
